Kirthi Gunasekera RATE PER 100,000 POPULATION 10 20 30 40 50 - - PowerPoint PPT Presentation

kirthi gunasekera
SMART_READER_LITE
LIVE PREVIEW

Kirthi Gunasekera RATE PER 100,000 POPULATION 10 20 30 40 50 - - PowerPoint PPT Presentation

Kirthi Gunasekera RATE PER 100,000 POPULATION 10 20 30 40 50 60 0 1984 INCIDENCE AND MORTALITY RATES OF TUBERCULOSIS IN SRI LANKA 1985 1986 1987 1988 PTB 1989 1990 1991 1992 1984 - 2005 1993 TOTAL TB 1994 1995 1996 1997


slide-1
SLIDE 1

Kirthi Gunasekera

slide-2
SLIDE 2

INCIDENCE AND MORTALITY RATES OF TUBERCULOSIS IN SRI LANKA 1984 - 2005

10 20 30 40 50 60 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 RATE PER 100,000 POPULATION PTB TOTAL TB Mortality Rate

slide-3
SLIDE 3

24y old Tamil boy is brought to A & E department of PGH Badulla with severe dyspnoea. He is tachypnoeic and gasping for breath O/E Pale, Cachectic and febrile with bilateral crepitation Within 2 hours of admission he had a Respiratory arrest & could not be revived despite ET intubation and manual ventilation.

He had been transferred from DH Passara where he had been treated one day and his sputum was found to be positive for AFB. 20th November 2008

slide-4
SLIDE 4

Chest x-ray revealed extensive bi lateral fibrocavitatory disease with areas of consolidation Questioning the father in retrospect, it revealed That the patient was not resident of Passara but working in tea boutique in Maradane - Colombo for 6 years He had been unwell with cough, wheezing and episodic fever for 1 1/2y. He had sought medications from over 8 doctors and had taken inward treatment from 2 teaching hospitals where he had been treated for bronchial asthma with repeated nebulizations.

At no point in his illness was chest x-ray or sputum examination performed !

slide-5
SLIDE 5

The Problems Associated With Delayed Diagnosis

Latent TB Infection

TB Disease Anti TB Treatment

Spread of disease in the community Progression of disease in patient Respiratory Cripple

slide-6
SLIDE 6

The key factors affecting the diagnosis of TB

PATIENT DOCTOR INVESTIGATIONS COMMUNITY

slide-7
SLIDE 7

Lack of awareness Social stigmatization Nature of Symptoms

PATIENT COMMUNITY

Inaccessibility to Health care Social stigmatization Myths

slide-8
SLIDE 8

SYMPTOMS OF PULMONARY TUBERCULOSIS

Nonspecific and Constitutional Unusual fatigue Tiredness Malaise Anorexia Pyrexia Weight Loss Night sweats Amenorrhoea

Respiratory Cough-2 wks Haemoptysis Chest pain SOB

slide-9
SLIDE 9

THE SUBTLE NATURE OF THE EARLY SYMPTOMS OF TUBERCULOSIS WITH POOR ACCESSEBILTY TO DIAGNOSTIC FACILITIES PLAYS A KEY ROLE IN THE DELAYED DIAGNOSIS OF THE DISEASE

slide-10
SLIDE 10

SOCIAL STIGMA – IS IT REAL in 2009? Does TB deprive you of all Human Rights?

slide-11
SLIDE 11

Lack of awareness Nature of Clinical signs Misdiagnosis False image Paucity of diagnostic aids Low priority

DOCTOR

slide-12
SLIDE 12

CLINICAL NICAL SIGNS S OF PULMONAR ONARY Y TUBERCULOS CULOSIS IS

Mild to moderate disease may have no clinical signs Generalized Pallor (Anaemia) fever weight loss Respiratory upper zone crackles

  • post tussive

signs of consolidation Localized wheeze Chronic Tuberculosis Tracheal deviation flattened chest cavity - amphoric breath sounds

slide-13
SLIDE 13

Differential Diagnosis

Differential Diagnosis Pointers to the Correct Diagnosis

  • Asthma
  • Intermittent symptoms,

Expiratory wheeze

  • C O P D
  • Smoking, Chronic symptoms,

generalized wheezing

  • Bronchiectasis
  • Large amounts of purulent

Sputum / Haemoptysis

  • Bronchial carcinoma
  • Risk factor (Smoking) / clubbing
  • Other infections, Eg:

Bacterial pneumonia Lung abscess Pneumocystis carinii

  • Response to antibiotic
  • Abscess with fluid level on CXR
  • Dyspnoea prominent
slide-14
SLIDE 14

Hi High gh Ri Risk Grou

  • ups

ps wi with h Inc ncreased eased Sus uscep eptib tibil ilit ity y to Tub uber ercul ulosis

  • sis

Nonspecific Decrease in Resistance Adolescence Senescence Malnutrition Post gastrectomy states Diabetes mellitus Alcoholism

Drug addicts

Decrease in Resistance Due to Hormonal Effects Pregnancy Therapy with adrenocortico steroids Decrease in Local Resistance Silicosis Decrease in Specific immunity Lymphomas Uremia Immunosuppressive therapy Sarcoidosis Live virus vaccination Acquired immunodeficiency syndrome (AIDS)`

Exposure to TB Patients

  • Family / close contacts
  • People living / working in

institutionalized Settings Eg: Prisons, Nursing homes, Refugee Camps

  • Healthcare Workers
slide-15
SLIDE 15

1% 74% 25%

0- 14 15-55 >55

FALSE IMAGE ?

AGE DISTRIBUTION

Changing Profiles

Wasted Cache tic Haemoptysis Elderly Healthy looking Mild cough Low grade fever Young

slide-16
SLIDE 16

Sites of Attack

80 % PREDOMINENTLY LUNGS BRAIN EYES LIVER INTESTINE SPINE

slide-17
SLIDE 17

PRIMARY TUBERCULOSIS

Lung - most important portal of entry

Inhalation Aerosol of TB Bacilli

Coughed up by a smear (+) TB patient

Disease transmission

slide-18
SLIDE 18

WHAT HAPPENS TO THE INHALED BACILLUS

TB Germ Natural Immunity

10% Minority

DISEASE

Majority

INFECTED

Germ - inactive No Symptoms Do not feel sick Do not spread the disease TB skin test (+) Immunity

(Magnified Approximately 30,000 times)

PRIMARY TUBERCULOSIS

Germ - active Symptoms Mild & Non Specific Pleurisy Signs unusual

slide-19
SLIDE 19

Clinical Features

POST PRIMARY TUBERCULOSIS

Nonspecific and Constitutional Unusual fatigue Tiredness Malaise Anorexia Pyrexia Weight Loss Night sweats Amenorrhoea

Respiratory Cough Haemoptysis Chest pain SOB

slide-20
SLIDE 20

POST PRIMARY TUBERCULOSIS

Signs Mild to moderate disease may have no clinical signs Generalized Pallor (Anaemia) fever weight loss clubbing Respiratory upper zone crackles

  • post tussive

signs of consolidation Localized wheeze Chronic Tuberculosis Tracheal deviation flattened chest cavity - amphoric breath sounds EPTB- 10% (Cervical lymphnodes pleural effusions)

slide-21
SLIDE 21

6 MILLION PEOPLE ARE CO-INFECTED - HIV- TB HIV PATIENTS ARE 25 TIMES MORE LIKELY TO GET TB

slide-22
SLIDE 22

Pathogenesis of TB / HIV

TB CD4 T lymphocyte Immunity HIV

  • Active TB
  • Immune Stimulation – TNF 
  • HIV / TB -

Opp Infection CD4

slide-23
SLIDE 23

Features of Pulmonary TB Clinical Picture Sputum smear result Chest X-ray Early Often resembles Post –primary TB Often positive Often cavities are seen Late Often resembles primary TB Often negative Often infiltrates With no cavity

Stage of HIV Infection

Clinical Picture of Pulmonary TB In HIV Seropositive Persons

slide-24
SLIDE 24

Sputum Microscopy Chest X ray Mantoux Test TB Culture

INVESTIGATIONS PCR Gamma Interferon Rapid Culture Adenosine De Aminase

slide-25
SLIDE 25

Mycobacterium Tuberculosis

Sputum microscopy

slide-26
SLIDE 26

SPUTUM MICROSCOPY

  • Not popular among Doctors &

patient

  • Lack of facility
  • Incorrect sample collection – saliva
  • Inadequate samples
  • Improper reading

Major tool for rapid diagnosis

slide-27
SLIDE 27

SPUTUM MICROSCOPY

Three Specimens Optimal

  • Spot sample - – 1st visit – give container
  • Early morning sample- collected by patient
  • Spot sample – 2nd visit

Sputum Microscopy

81% 93% 100% 0% 20% 40% 60% 80% 100% 120% First Second Third Cumilative Positivity First Second Third

slide-28
SLIDE 28

Sputum collection ? Deterrent to the Diagnosis

slide-29
SLIDE 29

TB Diagnosis

Specificity

10 20 30 40 50 60 70 80 90 100 AFB Microscopy X-ray

98% 50%

Microscopy is appropriate technology

Indicates

Infectiousness Risk of death Priority for treatment

slide-30
SLIDE 30

CURRENT TRENDS IN INVESTIGATING PTB IN SRI LANKA THE FACTS

  • Sputum microscopy - mainly confined to Chest Clinics
  • ESR and Chest X ray - main tools used by the majority

followed by Sputum Microscopy The 1st line investigation

NEED WE RELOOK AT INCEASING X RAY FACILITIES ALONG WITH SPUTUM MICROSCOPY ?

slide-31
SLIDE 31

TB Diagnosis

Over-diagnosed

10 20 30 40 50 60 70 80 90 100 Diagnosed by X-ray alone Actual cases

slide-32
SLIDE 32

Tuberculin Skin Test

Limited Value if TB prevalence is high Results: 0 - 9 mm

  • Negative

> 10mm

  • Positive

> 20mm

  • Strongly Positive
slide-33
SLIDE 33

33

TB INFECTED POPULATION

1/3 OF THE WORLDS POPULATION

  • 1.7 BILLION

> 50% IN SRI LANKA.

AMR 5% EUR 6% EMR 8% AFR 19% SEAR 34% WPR 28%

South – East Asia accounts for nearly 1/3rd of all Tuberculosis cases

slide-34
SLIDE 34

ARE WE OVER RELIANT ON MATOUX AND ESR ?

  • Mantoux is non specific and influenced by many factors
  • ESR does not correlate well with disease activity
  • ESR may be normal with active disease though

a very high ESR may indicate TB

MICROBIOLOGICAL / HISTOLOGICAL CONFIRMATION OF TUBERCULOSIS SHOULD BE GIVEN TOP PRIORITY

slide-35
SLIDE 35

Gamma Interferon

MTB produces antigens

– not seen in BCG & Non TB Myco bacteria

  • Early Secretory Antigen Target 6 – ( ESAT 6)
  • Culture Filtrate Protein 10 – ( CFP 10)

Pt’s Lymphocytes – culture with Antigens Gamma Interferon

slide-36
SLIDE 36

TB CULTURE

  • Highly specific
  • Grossly underutilized
  • Time consuming
  • Luxury test in state sector

Very helpful in species identification Identify Drug sensitivity patterns EPTB Smear negative TB

Rapid Culture Methods

Radiometric methods Oxygen consumption TB growths 7 – 10 days earlier Costly

slide-37
SLIDE 37

TB Diagnosis

  • Polymerase Chain Reaction (PCR)
  • Mycobacterial Antibodies
  • TB - Gamma Interferon
  • Adenosine De Aminase
slide-38
SLIDE 38

TB THOUGH DEADLY IS COMPLETELY CURABLE

  • Completely Free
  • Very Cheap
  • Long Duration
  • Multiple Drugs.

4 Antibiotics x 2 months 2 Antibiotics x 4 months.

slide-39
SLIDE 39

Essential Anti-TB Drugs

Drug Mode of Action Potency Side Effects Isoniazide

  • Bactericidal
  • High
  • Peripheral Neuropathy / Hepatitis

Rifampicin

  • Bactericidal
  • High
  • Nausea / Hepatitis / OCP

Pyrazinamide

  • Bactericidal
  • Low
  • Joint Pains / Hepatitis

Ethambutol

  • Bacteriostatic
  • Low
  • Optic Neuritis

Sreptomycine

  • Bactericidal
  • Low
  • Auditory / Vestibular Damage

Nephrotoxic Drug Isoniazide (H) Rifampicin (R) Pyrazinamide (Z) Ethambutol (E) Streptomycine (S) Intensive Phase

  • RHEZ Two Months

Continuation Phase

  • R H

Four Months Non Infective in Two Weeks Smear Negative in Two Months

slide-40
SLIDE 40

Prophylaxis in TB

INAH – 6/12 INAH + Rifampicine – 3/12

Primary Chaemoprophylaxis Person exposed but not infected Eg: Breast Fed Baby with sputum + Mum. HIV Positive / Mx Negative Secondary Chaemoprophylaxis Person infected but no clinical disease Eg: HIV + / Mx + Recent Mx Converters Mx > 10mm with Risk factor Mx > 10mm High prevalence groups

slide-41
SLIDE 41

TREATMENT PROBLEMS

  • Incorrect Chemotherapy Dose / Duration
  • Non compliance / Incomplete treatment
  • Irregular Drugs Supply
  • Poor Quality Drugs

CONSEQUENCES

  • Common Drugs Ineffective
  • Second line drugs – Severe adverse reactions / not very effective
  • Very High cost
  • High Mortality.
slide-42
SLIDE 42
slide-43
SLIDE 43

Second Line Drugs

Amikacim Kanamycin Capreomycin Ethionamide, Prothionamide Cycloserine, PAS Ofloxacin, Ciprofloxacin,

Surgical Resection

slide-44
SLIDE 44

XDR DR - TB TB

  • Extreme Drug Resistant TB
  • Form of MDR TB – resistant to
  • Quinolones + Injectables – Amikacin,Capreomycin,

Kanamycin -classes of the second line drugs

  • 4 – 19% 0f MDR Cases

South Africa – Kwazulu – Natal – HIV positive population Very high mortality – 52 out of 53 cases dead within 25 days

TD TDR R - TB TB

  • Totally Drug Resistant TB

2009 – Iran

slide-45
SLIDE 45

D

  • Directly

O

  • Observed

T

  • Treatment

S

  • Short Course

DOTS is the most cost effective strategy available for controlling the TB epidemic

slide-46
SLIDE 46
  • Accountability

TB Register

  • With the right drugs
  • In the right dose
  • At the right intervals

DOTS Ensures Treatment

  • Political commitment
  • Diagnosis by microscopy
  • Adequate supply of SCC drugs
  • Directly observed treatment
slide-47
SLIDE 47

The key factor to the diagnosis of Tuberculosis is the

Awareness that this Disease still Exists.